Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.
2.
3.

Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.

Hou H, Khan N, O'Hara JA, Grinberg OY, Dunn JF, Abajian MA, Wilmot CM, Makki M, Demidenko E, Lu S, Steffen RP, Swartz HM.

Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):834-43.

PMID:
15183487
4.

Effects of enhanced oxygen release from hemoglobin by RSR13 in an acute renal failure model.

Burke TJ, Malhotra D, Shapiro JI.

Kidney Int. 2001 Oct;60(4):1407-14.

5.

Allosteric modification of oxygen delivery by hemoglobin.

Wahr JA, Gerber M, Venitz J, Baliga N.

Anesth Analg. 2001 Mar;92(3):615-20.

PMID:
11226087
6.

Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation.

Khandelwal SR, Randad RS, Lin PS, Meng H, Pittman RN, Kontos HA, Choi SC, Abraham DJ, Schmidt-Ullrich R.

Am J Physiol. 1993 Oct;265(4 Pt 2):H1450-3.

PMID:
8238433
7.

Effects of a synthetic allosteric modifier of hemoglobin oxygen affinity on outcome from global cerebral ischemia in the rat.

Grocott HP, Bart RD, Sheng H, Miura Y, Steffen R, Pearlstein RD, Warner DS.

Stroke. 1998 Aug;29(8):1650-5.

8.

RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs.

Pagel PS, Hettrick DA, Montgomery MW, Kersten JR, Steffen RP, Warltier DC.

J Pharmacol Exp Ther. 1998 Apr;285(1):1-8.

9.

Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13.

Amorino GP, Lee H, Holburn GE, Paschal CB, Hercules SK, Shyr Y, Steffen RP, Choy H.

Radiat Res. 2001 Sep;156(3):294-300.

PMID:
11500138
10.

Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy.

Steffen RP, Liard JF, Gerber MJ, Hoffman SJ.

Adv Exp Med Biol. 2003;530:249-59.

PMID:
14562722
11.

RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery following hypothermic cardiopulmonary bypass.

Kilgore KS, Shwartz CF, Gallagher MA, Steffen RP, Mosca RS, Bolling SF.

Circulation. 1999 Nov 9;100(19 Suppl):II351-6.

12.

Modeling of the response of ptO2 in rat brain to changes in physiological parameters.

Grinberg OY, Hou H, Roche MA, Merlis J, Grinberg SA, Khan N, Swartz HM, Dunn JF.

Adv Exp Med Biol. 2005;566:111-8.

PMID:
16594142
13.

Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat.

Sarraf-Yazdi S, Sheng H, Grocott HP, Bart RD, Pearlstein RD, Steffen RP, Warner DS.

Brain Res. 1999 May 1;826(2):172-80.

PMID:
10224294
14.

Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.

Kleinberg L, Grossman SA, Piantadosi S, Pearlman J, Engelhard H, Lesser G, Ruffer J, Gerber M.

J Clin Oncol. 1999 Aug;17(8):2593-603.

PMID:
10561327
15.

Reducing hemoglobin oxygen affinity does not increase hydroxyl radicals after acute subdural hematoma in the rat.

Doppenberg EM, Rice MR, Alessandri B, Qian Y, Di X, Bullock R.

J Neurotrauma. 1999 Feb;16(2):123-33.

PMID:
10098957
16.

Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity.

Weiss RG, Mejia MA, Kass DA, DiPaula AF, Becker LC, Gerstenblith G, Chacko VP.

J Clin Invest. 1999 Mar;103(5):739-46.

17.

Effects of FI(O(2)) on hemodynamic responses and O(2) transport during RSR13-induced reduction in P(50).

Eichelbrönner O, Sielenkämper A, D'Almeida M, Ellis CG, Sibbald WJ, Chin-Yee IH.

Am J Physiol. 1999 Jul;277(1 Pt 2):H290-8.

PMID:
10409208
18.

Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.

Wainwright MS, Sheng H, Sato Y, Mackensen GB, Steffen RP, Pearlstein RD, Warner DS.

Am J Physiol Heart Circ Physiol. 2002 May;282(5):H1863-70.

PMID:
11959653
19.

Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.

Eichelbrönner O, D'Almeida M, Sielenkämper A, Sibbald WJ, Chin-Yee IH.

Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H92-101.

PMID:
12063279

Supplemental Content

Support Center